KalVista Pharmaceuticals: Sebetralstat Success Eyes FDA Approval

KalVista Pharmaceuticals Achieves Key Goals in Late-Stage Study for Hereditary Angioedema Therapy

KalVista Pharmaceuticals announced on Tuesday that its late-stage study for sebetralstat therapy, aimed at treating hereditary angioedema, has achieved its key goals. The clinical-stage pharmaceutical company, based in Cambridge, Massachusetts, revealed that the Phase study successfully met all primary and key secondary endpoints. This groundbreaking development demonstrates the statistically and clinically significant efficacy of sebetralstat in addressing the rare genetic condition, which causes distressing and incapacitating episodes of tissue swelling in different parts of the body.